---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-088942"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:44.739676+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eyenovia Q2 net loss $11.1M; plans Gen-2 Optejet submission 2025 with Mydcombi

## Summary
- Net loss $11.1M ($0.21/share) vs $6.2M ($0.16/share) in Q2 2023; includes $2.9M MicroPine license reacquisition expense.
- Cash $2.3M at June 30; $5.8M gross equity proceeds after quarter; expects funding through Phase 3 CHAPERONE data.
- Following FDA meeting, plans Gen-2 Optejet validation in Q4 2024 and regulatory submission 2025 with Mydcombi as lead.
- Phase 3 CHAPERONE study of MicroPine; analysis expected Q4 2024.
- Mydcombi launched in 63 new offices; targeting 263 by Q3 end; dry eye collaborations with Formosa, Senju, SGN.

## SEC filing metadata
- accession: 0001104659-24-088942
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465924088942/0001104659-24-088942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465924088942/tm2421563d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-088942
- JSON: https://secwatch.observer/filing/0001104659-24-088942.json
- Plain text: https://secwatch.observer/filing/0001104659-24-088942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.